Personalize your patients’ cancer treatment

Somatic testing is important for cancer patients. But did you know that germline genetic testing is needed to get a more complete story?¹ Germline genetic results can identify patients who can benefit from targeted treatments and objectively assess risk levels.
Hero image of woman

Data presented at ASCO suggest that genetic testing is underutilized in cancer treatment²

1 in 8 infographic

1 in 8

cancer patients has a germline variant

A recent JAMA Oncology study found that germline testing for all patients with cancer—including lung, colorectal, prostate, pancreatic, and ovarian—uncovered pathogenic germline variants in 13.3% of patients.¹

48% have no family history infographic

Nearly half of those patients didn’t have a suggestive family history

Testing only patients with suggestive family histories—as defined by clinical practice guidelines—misses 48% of patients with a pathogenic germline variant.¹ Germline testing of all cancer patients ensures that you don’t miss genetic information that can guide their care.¹ Invitae’s simple workflow makes testing all patients easy.
woman on green shape

1 in 3

patients with a germline variant could benefit from tailored treatments

In the JAMA Oncology study, nearly 1 in 3 patients with a positive genetic result could have benefited from tailored treatment, including PARP inhibitors, type of surgery or chemotherapy, or enrollment in clinical trials.¹,³

Across cancer types, universal germline testing can help personalize your treatment approach

Recent research suggests that the percentage of colorectal cancer patients with germline variants is much higher than previously thought: more than 18%.² Of these patients, as many as 67% could be eligible for precision therapy (such as PD-1/PD-L1 inhibitors) and/or clinical treatment trials (such as for PARP inhibitors).² The Invitae Multi-Cancer Panel is a cross-cancer test with 20 genes linked to colorectal cancer.
Growing evidence shows that germline genetic testing for all breast cancer patients can be beneficial, informing more targeted care and treatment strategies.⁴ A recent study found that germline result-specific management recommendations exist for 88% of breast cancer patients with positive results. In addition, 65% of breast cancer patients with positive results became eligible for targeted therapies and/or clinical treatment trials.⁵ The Invitae Multi-Cancer Panel is a cross-cancer test with 23 genes linked to breast cancer.
Despite guidelines recommending that all ovarian cancer patients undergo germline genetic testing, more than two-thirds of patients remain untested.⁶ Test results are important for identifying patients who need targeted therapy. For example, targeted treatments such as PARP inhibitors (sometimes preceded by platinum-based chemotherapy) can improve progression-free survival outcomes in both frontline and recurrent settings.⁷ The Invitae Multi-Cancer Panel is a cross-cancer test with 13 genes linked to ovarian cancer.
Up to 17% of men with prostate cancer, across all stages of disease, harbor a germline variant that can impact management and treatment decisions.⁸ For metastatic prostate cancer patients, the number is even higher at 25%; for these patients, tailored treatments including PARP inhibitors and immunotherapy can have significant diagnostic and therapeutic utility.⁹,¹⁰ PARP inhibitors have received FDA approval for treatment in some prostate cancers after previous therapies have failed.¹¹ The Invitae Multi-Cancer Panel is a cross-cancer test with 12 genes linked to prostate cancer.
Germline genetic testing for patients with pancreatic cancer can help assess precision medicine options and evaluate inclusion in clinical trials. Precision therapy has become a new standard of care for patients who test positive.¹²,¹³ In a recent study, 11% of unselected pancreatic cancer patients had positive germline results. The majority (89%) of the positive results conferred eligibility for DNA damage repair (DDR) gene-specific precision therapies or clinical treatment trials.¹⁴ The Invitae Multi-Cancer Panel is a cross-cancer test with 20 genes linked to pancreatic cancer.

Test today for their tomorrow

Patient stories - ob and onc journey pages carousel, click to skip carousel

Ready to learn more about the JAMA Oncology study supporting germline genetic testing for all cancer patients?

ASCO=American Society of Clinical Oncology
JAMA=Journal of the American Medical Association


1. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021 Feb 1;7(2):230-237. doi:10.1001/jamaoncol.2020.6252.
2. Nielsen SM, Dalton J, Hatchell KE, et al. Clinical impact of medical policy supporting universal germline testing for patients with colorectal cancer. To be presented at: ASCO Annual Meeting; June 4-8, 2021.
3. Naumann RW, Morris JC, Tait DL, et al. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. Gynecol Oncol. 2018;151(3)477-480. doi:10.1016/j.ygyno.2018.10.003.
4. Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018;37(6):453-460. doi:10.1200/JCO.18.01631.
5. Nielsen SM, Beitsch PD, Whitworth PW, et al. Comprehensive germline multigene panels change care and inform treatment strategies for breast cancer patients. Presented at: NSGC Annual Meeting; November 18-22, 2020.
6. Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. J Clin Oncol. 2021. doi:10.1200/JCO.20.02785.
7. Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108-121. doi:10.1097/AOG.0000000000004173.
8. Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5(4):523-528. doi: 10.1001/jamaoncol.2018.6760.
9. Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645-651. doi: 10.1038/s41588-018-0078-z.
10. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228. doi:10.1016/j.cell.2015.05.001.
11. Ni Raghallaigh H, Eeles R. Genetic predisposition to prostate cancer: an update. Fam Cancer. 2021. doi:10.1007/s10689-021-00227-3.
12. Dudley B, Karloski E, Monzon FA, et al. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer. 2018;124(8):1691-1700. doi: 10.1002/cncr.31242.
13. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-327. doi: 10.1056/NEJMoa1903387.
14. Esplin E. Increasing access for patients with pancreatic cancer to germline genetic testing: Clinical impacts across disease stage and ethnicity: Presented at NSGC Annual Meeting; November 18-22, 2020.